Steve Schonfeld’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Steve Schonfeld’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,953,712	Closed	-$8.21M	–	2724
2023 Q1	$8.21M	Buy	1,953,712 +206,112	+12%	+$1.07M	0.08%	334
2022 Q4	$10.5M	Buy	1,747,600 +418,124	+31%	+$2.28M	0.09%	292
2022 Q3	$7.74M	Buy	1,329,476 +481,776	+57%	+$3M	0.06%	389
2022 Q2	$5.06M	Buy	847,700 +638,100	+304%	+$3.27M	0.05%	467
2022 Q1	$978K	Buy	209,600 +38,400	+22%	+$115K	0.01%	1003
2021 Q4	$424K	Buy	171,200 +95,200	+125%	+$233K	﹤0.01%	1346
2021 Q3	$224K	Sell	76,000 -1,000	-1%	-$2.72K	﹤0.01%	1709
2021 Q2	$193K	Buy	77,000 +36,474	+90%	+$87.5K	﹤0.01%	1689
2021 Q1	$117K	Sell	40,526 -4,574	-10%	-$14.9K	﹤0.01%	1615
2020 Q4	$145K	Buy	+45,100	New	+$150K	﹤0.01%	1398

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Steve Schonfeld's CTIC Position: Q2 2023 in Review

Steve Schonfeld sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,953,712 shares — an estimated $8.21M sold.

Steve Schonfeld first reported a position in CTIC in Q4 2020 and held it in 10 quarters. The position peaked at $10.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Steve Schonfeld reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Steve Schonfeld sold 1,953,712 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $8.21M.
Steve Schonfeld first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 10 quarters.
Steve Schonfeld's CTI BioPharma Corp. (DE) Common Stock position peaked at $10.5M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.